Type 2 diabetes Diabetic kidney disease
Conditions
Interventions
Canagliflozin (100mg) is orally administered once a day
SGLT2 inhibitor
Sponsors
Mori Katsuhito
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetes 2) Signed consent form 3) Age >= 20 years and = 6.5% and < 10% 5) Patients without any SGLT2 inhibitors at least 2 weeks before first BOLD MRI (at least 17 days before first canagliflozin administration)
Exclusion criteria
Exclusion criteria: 1) Pregnancy or breat-feeding and its possibility 2) Known allergy to canagliflozin 3) Contraindication for MRI (pacemaker or claustrophobia) 4) Past history of recurrent urinary tract or genital infections 5) Nephrotic sydrome 6) Diuretics or NSAIDs 7) Severe renal dysfuntion (eGFR triple upper limit of facility criterion) 10) Malignant tumors 11) Severe heart failure (NYHA class III or IV) 12) Patients who participate in any clinical trial except this trial 13) Patients whom principal investigator judges as inappropriate for the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in T2* value before and after canagliflozin treatmnet | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in erythropoietin, fasting plasma glucose, HbA1c glycated albumin, albuminuria, proteinuria, urinary electrolytes (sodium, potassium, chloride), urinary tubular damage marker (beta 2MG, NAG), and resistance index before and after canagliflozin treatmnet | — |
Contacts
Public ContactKatsuhito Mori
Osaka Metropolitan University Hospital
Outcome results
None listed